

Parabolic Drugs Limited

Registered Office: SCO. 99 - 100, Top Floor, Sector - 17B, Chandigarh

Corporate Office: 9 AB, Taimoor Nagar, New Friends Colony, New Delhi

Unaudited Financial Results for the Quarter Ended 30th June, 2011

(Rs. Crores)

Particulars	Quarter ended 30/06/2011	Corresponding Quarter in the previous year ended 30/06/2010	Year ended 31/03/2011
	Unaudited	Unaudited	Audited
a) Gross Sales	205.47	140.15	675.30
Less : Excise Duty	(19.28)	(12.67)	(59.28)
Net Sales/Income from Operations	186.19	127.48	616.02
(b) Other Operating Income	2.68	0.32	19.16
1. Total Income	188.87	127.80	635.18
2. Expenditure			
a) (Increase)/Decrease in stock in trade and work in progress	(64.83)	(16.19)	(89.78)
b) Consumption of Raw Materials	198.37	106.46	541.09
c) Employees Cost	4.73	3.46	16.93
d) Depreciation & Amortisations	7.75	4.35	17.69
e) Other Expenditure	8.80	8.33	39.81
f) Total	154.82	106.41	525.74
3. Profit from Operations before Other Income, Interest & Exceptional Items	34.06	21.39	109.44
4. Other Income			
5. Profit before Interest & Exceptional Items (3 + 4)	34.06	21.39	109.44
6. Interest	14.14	7.89	40.76
7. Profit after interest but before Exceptional Items (5-6)	19.92	13.50	68.68
8. Exceptional Items	-	-	-
9. Profit (+)/Loss(-) from Ordinary Activities before tax (7 + 8)	19.92	13.50	68.68
10. Tax expenses	4.73	2.97	15.81
11. Net Profit(+)/ Loss(-) from Ordinary Activities after tax (9 - 10)	15.18	10.53	52.87
12. Extra Ordinary Items			
13. Net Profit (+)/ Loss(-) for the period (11-12)	15.18	10.53	52.87
14. Paid-up equity share capital (Face Value of the Share shall be indicated) (Rs. 10/- each)	61.89	61.89	61.89
15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-
16. Earnings Per Share (EPS)			
- Basic EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	2.45	2.77	9.43
- Diluted EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	2.45	2.77	9.43
- Basic EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	2.45	2.77	9.43
- Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	2.45	2.77	9.43
17. Public Shareholding :			
- Number of Shares	38257907	38346994	38257907
- Percentage of Shareholding	61.81	61.96	61.81
18. Promoters and Promoter Group Shareholding (non-encumbered) :			
- Number of shares	23634107	23545020	23634107
- Percentage of shares (as a % of the to total shareholding of promoter and promoter group)	100.00	100.00	100.00
- Percentage of shares (as a % of the to total share capital of the company)	38.19	38.04	38.19

Notes :

1. The above results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 13th August
2. During the period the Company has : Filed one Drug Master Files (DMF) with USFDA for one of its Non-Beta Lactum Products, one Certificate of Suitability (COS) with EDQM and one patent for Non-beta molecule with Indian Patent Office.
3. There were no investor complaints pending at the beginning of the quarter. No complaint received from the shareholders during the quarter and no complaint was pending at the end of the quarter.
4. The above financial results are on stand alone basis.
5. The company operates in only one Business Segment.
6. Figures of the previous year have been rearranged/regrouped wherever necessary.

For Parabolic Drugs Ltd.

Place : Chandigarh

Date : 13th August, 2011

Pranav Gupta
Managing Director